Gyre Therapeutics, Inc. Research and Development Expense (Excluding Acquired in Process Cost)
Gyre Therapeutics, Inc. (GYRE) reported Research and Development Expense (Excluding Acquired in Process Cost) of $6.74 million for the 3-month period ending 2026-03-31, per its 10-Q filed 2026-05-08.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost · last filed 2026-05-08
- Gyre Therapeutics, Inc. research and development expense (excluding acquired in process cost) for the quarter ending 2026-03-31 was $6.74M, a 117.71% increase year-over-year.
- Gyre Therapeutics, Inc. research and development expense (excluding acquired in process cost) for the quarter ending 2025-12-31 was $4.82M, a 29.71% increase year-over-year.
- Gyre Therapeutics, Inc. research and development expense (excluding acquired in process cost) for the quarter ending 2025-09-30 was $2.36M, a 14.85% decline year-over-year.
- Gyre Therapeutics, Inc. research and development expense (excluding acquired in process cost) for the quarter ending 2025-06-30 was $3.42M, a 2.09% increase year-over-year.
- Gyre Therapeutics, Inc. research and development expense (excluding acquired in process cost) for fiscal 2025 was $13.70M, a 13.92% increase from fiscal 2024.
- Gyre Therapeutics, Inc. research and development expense (excluding acquired in process cost) for fiscal 2024 was $12.02M, a 12.74% decline from fiscal 2023.
- Gyre Therapeutics, Inc. research and development expense (excluding acquired in process cost) for fiscal 2023 was $13.78M, a 17.42% decline from fiscal 2022.
- Gyre Therapeutics, Inc. research and development expense (excluding acquired in process cost) for fiscal 2022 was $16.69M, a 75.78% decline from fiscal 2021.
| Period end | Research and Development Expense (Excluding Acquired in Process Cost) 3 month | Research and Development Expense (Excluding Acquired in Process Cost) 6 month | Research and Development Expense (Excluding Acquired in Process Cost) 9 month | Research and Development Expense (Excluding Acquired in Process Cost) 12 month | Research and Development Expense (Excluding Acquired in Process Cost) 12 month as first filed |
|---|---|---|---|---|---|
| 2026-03-31 | $6.74M 10-Q · filed 2026-05-08 | $11.55M derived: sum of 2 quarters · filed 2026-05-08 | $13.92M derived: sum of 3 quarters · filed 2026-05-08 | $17.34M derived: sum of 4 quarters · filed 2026-05-08 | |
| 2025-12-31 | $4.82M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-13 | $7.18M derived: sum of 2 quarters · filed 2026-03-13 | $10.60M derived: sum of 3 quarters · filed 2026-03-13 | $13.70M 10-K · filed 2026-03-13 | |
| 2025-09-30 | $2.36M 10-Q · filed 2025-11-07 | $5.79M derived: sum of 2 quarters · filed 2025-11-07 | $8.88M 10-Q · filed 2025-11-07 | $12.60M derived: sum of 4 quarters · filed 2026-05-08 | |
| 2025-06-30 | $3.42M 10-Q · filed 2025-08-11 | $6.52M 10-Q · filed 2025-08-11 | $10.23M derived: sum of 3 quarters · filed 2026-05-08 | $13.01M derived: sum of 4 quarters · filed 2026-05-08 | |
| 2025-03-31 | $3.10M 10-Q · filed 2026-05-08 | $6.81M derived: sum of 2 quarters · filed 2026-05-08 | $9.58M derived: sum of 3 quarters · filed 2026-05-08 | $12.94M derived: sum of 4 quarters · filed 2026-05-08 | |
| 2024-12-31 | $3.71M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-13 | $6.49M derived: sum of 2 quarters · filed 2026-03-13 | $9.84M derived: sum of 3 quarters · filed 2026-03-13 | $12.02M 10-K · filed 2026-03-13 | |
| 2024-09-30 | $2.77M 10-Q · filed 2025-11-07 | $6.13M derived: sum of 2 quarters · filed 2025-11-07 | $8.31M 10-Q · filed 2025-11-07 | $12.88M derived: sum of 4 quarters · filed 2025-11-07 | |
| 2024-06-30 | $3.35M 10-Q · filed 2025-08-11 | $5.54M 10-Q · filed 2025-08-11 | $10.11M derived: sum of 3 quarters · filed 2025-08-11 | $13.11M derived: sum of 4 quarters · filed 2025-08-11 | |
| 2024-03-31 | $2.18M 10-Q · filed 2025-05-09 | $6.75M derived: sum of 2 quarters · filed 2025-05-09 | $9.76M derived: sum of 3 quarters · filed 2025-05-09 | $13.33M derived: sum of 4 quarters · filed 2025-05-09 | |
| 2023-12-31 | $4.57M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-17 | $7.58M derived: sum of 2 quarters · filed 2025-03-17 | $11.14M derived: sum of 3 quarters · filed 2025-03-17 | $13.78M 10-K · filed 2025-03-17 | |
| 2023-09-30 | $3.01M 10-Q · filed 2024-11-13 | $6.58M derived: sum of 2 quarters · filed 2024-11-13 | $9.21M 10-Q · filed 2024-11-13 | ||
| 2023-06-30 | $3.57M 10-Q · filed 2024-08-13 | $6.20M 10-Q · filed 2024-08-13 | |||
| 2023-03-31 | $2.63M 10-Q · filed 2024-05-13 | ||||
| 2022-12-31 | $16.69M 10-K · filed 2024-03-27 | $13.04M 10-K · filed 2023-03-30 | |||
| 2021-12-31 | $68.89M 10-K · filed 2023-03-30 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| GERON CORP (GERN) | United States | $0.803B | -12.14 |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Avalo Therapeutics, Inc. (AVTX) | United States | $0.842B | -9.74 |
| Aclaris Therapeutics, Inc. (ACRS) | United States | $0.792B | -9.78 |
| Olema Pharmaceuticals, Inc. (OLMA) | United States | $0.790B | -5.35 |
| Wave Life Sciences, Inc. (WVE) | $0.780B | -5.56 | |
| ARDELYX, INC. (ARDX) | United States | $0.857B | -22.86 |
| Design Therapeutics, Inc. (DSGN) | United States | $0.766B | -12.78 |